Current Oncology Reports

, Volume 3, Issue 3, pp 271–278 | Cite as

Upfront transplantation for poor-risk aggressive non-hodgkin lymphoma and hodgkin’s disease: Who benefits?

  • Tarun Kewalramani
  • Craig H. Moskowitz

Abstract

High-dose therapy with autologous stem-cell transplantation is the standard treatment for patients with relapsed or primary refractory Hodgkin’s disease or non-Hodgkin lymphoma. The efficacy of the treatment in this setting has prompted extensive investigation of its role in upfront therapy for patients with a poor prognosis. Although the preliminary data appear promising, definitive results are still lacking, and upfront transplantation remains investigational. Newer regimens for the treatment of advanced-stage Hodgkin’s disease appear to confer cure rates of approximately 85% to 90%. Thus, only a small minority of patients may potentially benefit from more aggressive therapy such as upfront transplantation. A reliable method of identifying these patients is yet to be determined. Upfront transplantation should be evaluated in these patients once they are identified.

References and Recommended Reading

  1. 1.
    The International Non-Hodgkin’s Lymphoma Prognostic Factors Project: A predictive model for aggressive non-Hodgkin’s lymphoma. N Engl J Med 1993, 329:987–994.CrossRefGoogle Scholar
  2. 2.
    Philip T, Guglielmi C, Hagenbeek A, et al.: Autologous bone marrow transplantation as compared with salvage chemotherapy in relapses of chemotherapy-sensitive non-Hodgkin’s lymphoma. N Engl J Med 1995, 333:1540–1545.PubMedCrossRefGoogle Scholar
  3. 3.
    Kewalramani T, Hedrick EE, Donnelly GB, et al.: High-dose chemoradiotherapy and autologous stem cell transplantation for patients with primary refractory aggressive non-Hodgkin’s lymphoma: an intention-to-treat analysis. Blood 2000, 96:2399–2404.PubMedGoogle Scholar
  4. 4.
    Prince HM, Crump M, Imrie K, et al.: Intensive therapy and autotransplant for patients with an incomplete response to front-line therapy for lymphoma. Ann Oncol 1996, 7:1043–1079.PubMedGoogle Scholar
  5. 5.
    Vose JM, Rowlings PA, Lazarus HM, et al.: Multivariate analysis of autotransplants for patients with aggressive non-Hodgkin’s lymphoma failing primary induction therapy [abstract]. Blood 1997, 90:594a.Google Scholar
  6. 6.
    Horning SJ, Rosenberg SA, Hoppe RT: Brief chemotherapy (Stanford V) and adjuvant radiotherapy for bulky or advanced Hodgkin’s disease: an update. Ann Oncol 1996, 7(suppl 4):S105-S108.Google Scholar
  7. 7.
    Sieber M, Ruffer U, Jostin A, Diehl V: Treatment strategies of Hodgkin’s disease: current strategies of the German Hodgkin’s Lymphoma Study Group. Ann Oncol 1999, 10(suppl 6):S23-S29.CrossRefGoogle Scholar
  8. 8.
    Diehl V, Tesch H, Franklin J, et al.: BEACOPP chemotherapy for advanced Hodgkin’s disease: recent analysis of HD9 trial (GHSG) results confirms improved efficacy due to moderate dose escalation [abstract]. Blood 1999, 94(suppl 1):527a. This randomized trial demonstrates the superior failure-free survival conferred by escalated BEACOPP over standard BEACOPP or COPP/ABVD.Google Scholar
  9. 9.
    Canellos GP, Anderson JR, Propert KJ, et al.: Chemotherapy of advanced Hodgkin’s disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992, 327:1478–1484.PubMedCrossRefGoogle Scholar
  10. 10.
    Carella AM, Principe M, Pungolino E, et al.: Twelve years experience with high-dose therapy and autologous stem cell transplantation for high-risk Hodgkin’s disease patients in first remission after MOPP/ABVD chemotherapy. Leuk Lymphoma 1996, 21:63–70.PubMedGoogle Scholar
  11. 11.
    Nademanee A, Molina A, Fung H, et al.: High-dose chemo/ radiotherapy and autologous bone marrow or stem cell transplantation for poor-risk advanced stage Hodgkin’s disease during first partial or complete remission. Biol Blood Marrow Transplant 1999, 5:292–298. This retrospective analysis shows an excellent outcome for selected patients with poor-prognosis advanced Hodgkin’s disease who underwent HDT/ASCT in first complete response or partial response.PubMedCrossRefGoogle Scholar
  12. 12.
    Straus DJ, Gaynor JJ, Meyers J, et al.: Prognostic factors among 185 adults with newly diagnosed advanced Hodgkin’s disease treated with alternating potentially noncrossresistant chemotherapy and intermediate-dose radiation therapy. J Clin Oncol 1990, 8:1173–1186.PubMedGoogle Scholar
  13. 13.
    Hasenclever D, Diehl V: A prognostic score for advanced Hodgkin’s disease. N Engl J Med 1998, 339:1506–1514.PubMedCrossRefGoogle Scholar
  14. 14.
    Harris NL, Jaffe ES, Diebold J, et al.: World Health Organization classification of neoplastic disease of hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting—Airlie House, Virginia, November 1997. J Clin Oncol 1999, 17:3835–3849.PubMedGoogle Scholar
  15. 15.
    The Non-Hodgkin’s Lymphoma Classification Project: National Cancer Institute sponsored study of classifications of non-Hodgkin’s lymphomas: summary and description of a working formulation for clinical usage. Cancer 1982, 49:2112–2135.CrossRefGoogle Scholar
  16. 16.
    Shipp M: Prognostic factors in aggressive non-Hodgkin’s lymphoma: who has "high-risk" disease? Blood 1994, 5:1165–1173.Google Scholar
  17. 17.
    Gulati SC, Shank B, Black P, et al.: Autologous bone marrow transplantation for patients with poor-prognosis lymphoma. J Clin Oncol 1988, 8:1303–1313.Google Scholar
  18. 18.
    Nademanee A, Schmidt GM, O’Donnell MR, et al.: High-dose chemoradiotherapy followed by autologous bone marrow transplantation as consolidation therapy during first complete remission in adult patients with poor-risk aggressive lymphoma: a pilot study. Blood 1992, 80:1130–1134.PubMedGoogle Scholar
  19. 19.
    Freedman AS, Takvorian T, Neuberg D, et al.: Autologous bone marrow transplantation in poor-prognosis intermediategrade and high-grade B-cell non-Hodgkin’s lymphoma in first remission: a pilot study. J Clin Oncol 1993, 11:931–936.PubMedGoogle Scholar
  20. 20.
    Santini G, Congiu AM, Coser P, et al.: High dose therapy (HDT) with autologous bone marrow transplantation rescue (ABMT) in 100 aggressive poor-prognosis non-Hodgkin’s lymphomas: a report of the non-Hodgkin’s lymphoma cooperative study group [abstract]. Proc ASCO 1993, 12:377.Google Scholar
  21. 21.
    Cortelazzo S, Rossi A, Viero P, et al.: BEAM chemotherapy and autologous haemopoietic progenitor cell transplantation as front-line therapy for high-risk patients with diffuse large cell lymphoma. Br J Haematol 1997, 99:379–385.PubMedCrossRefGoogle Scholar
  22. 22.
    Vitolo U, Cortelazzo S, Liberati AM, et al.: Intensified and high-dose chemotherapy with granulocyte colony-stimulating factor and autologous stem-cell transplantation support as first line therapy in high-risk diffuse large-cell lymphoma. J Clin Oncol 1997, 15:491–498.PubMedGoogle Scholar
  23. 23.
    Haioun C, Lepage E, Gisselbrecht C, et al.: Comparison of autologous bone marrow transplantation with sequential chemotherapy for intermediate-grade and high-grade non-Hodgkin’s lymphoma in first complete remission: a study of 464 patients. J Clin Oncol 1994, 12:2543–2551.PubMedGoogle Scholar
  24. 24.
    Haioun C, Lepage E, Gisselbrecht C, et al.: Survival benefit of high dose therapy in poor-risk aggressive non-Hodgkin’s lymphoma: final analysis of the prospective LNH87-2 protocol—A Groupe d’Etudes des Lymphomes de l’Adulte study. J Clin Oncol 2000, 18:3025–3030. This report of a retrospective cohort study analyzes the benefit of HDT/ASCT among patients with 2 to 3 risk factors of the AAIPI who achieved a complete remission.PubMedGoogle Scholar
  25. 25.
    Santini G, Salvagno L, Leoni P, et al.: VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin’s lymphomas: results of a prospective randomized trial by the Non-Hodgkin’s Lymphoma Cooperative Study Group. J Clin Oncol 1998, 16:2796–2802.PubMedGoogle Scholar
  26. 26.
    Kluin-Nelemans JC, Zagonel V, Thomas J, et al.: Consolidation ABMT after standard chemotherapy vs CHVmP/BV alone for primary intermediate and high grade NHL: a randomized phase III EORTC study [abstract]. Proc ASCO 1999, 18:2a.Google Scholar
  27. 27.
    Gianni AM, Bregni M, Siena S, et al.: High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med 1997, 336:1290–1297.PubMedCrossRefGoogle Scholar
  28. 28.
    Milpied N, Deconninck E, Colombat P, et al.: Frontline high-dose chemotherapy (HDC) with autologous stem cell transplantation compared to standard CHOP regimen: a randomized trial for adult patients with non IPI high-risk intermediate or high grade lymphomas (NHL) [abstract]. Blood 1999, 94(suppl 1):610a.Google Scholar
  29. 29.
    Haq R, Sawka CA, Franssen E, Berinstein NL: Significance of a partial or slow response to front-line chemotherapy in the management of intermediate-grade or high-grade non-Hodgkin’s lymphoma: a literature review. J Clin Oncol 1994, 12:1074–1084.Google Scholar
  30. 30.
    Verdonck LF, van Putten WLJ, Hagenbeek A, et al.: Comparison of CHOP chemotherapy with autologous bone marrow transplantation for slowly responding patients with aggressive non-Hodgkin’s lymphoma. N Engl J Med 1995, 332:1045–1051.PubMedCrossRefGoogle Scholar
  31. 31.
    Pettengel R, Radford JA, Morgenstern GR, et al.: Survival benefit from high-dose therapy with autologous blood progenitorcell transplantation in poor-prognosis non-Hodgkin’s lymphoma. J Clin Oncol 1996, 14:586–592.Google Scholar
  32. 32.
    Nademanee A, Molina A, O’Donnell MR, et al.: Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: International Index high and high-intermediate risk group. Blood 1997, 90:3844–3852.PubMedGoogle Scholar
  33. 33.
    Reyes F, Lepage E, Morel P, et al.: Failure of first-line inductive high-dose chemotherapy (HDC) in poor-risk patients (PTS) with aggressive lymphoma: updated results of the randomized LNH93-3 study [abstract]. Blood 1997, 90:594a.Google Scholar
  34. 34.
    Gherlinzoni F, Martelli M, Tura S: Early autologous stem cell transplantation (ASCT) versus conventional first-line chemotherapy in high-risk aggressive non-Hodgkin’s lymphomas (NHL): an Italian multicenter randomized trial [abstract]. Blood 2000, 96:481a.Google Scholar
  35. 35.
    Gascoyne RD, Adomat SA, Krajewski S, et al.: Prognostic significance of bcl-2 protein expression and bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin’s lymphoma. Blood 1997, 90:244–251.PubMedGoogle Scholar
  36. 36.
    Alizadeh A, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503–511.PubMedCrossRefGoogle Scholar
  37. 37.
    Adida C, Haioun C, Gaulard P, et al.: Prognostic significance of surviving expression in diffuse large B-cell lymphomas. Blood 2000, 96:1921–1925.PubMedGoogle Scholar
  38. 38.
    Carella AM, Carlier P, Congiu A, et al.: Autologous bone marrow transplantation as adjuvant treatment for high-risk Hodgkin’s disease in first complete remission after MOPP/ ABVD protocol. Bone Marrow Transplant 1991, 8:99–103.PubMedGoogle Scholar
  39. 39.
    Fleury J, Legros M, Colombat P, et al.: High-dose therapy and autologous bone marrow transplantation in first complete or partial remission for poor prognosis Hodgkin’s disease. Leuk Lymphoma 1996, 20:259–266.PubMedGoogle Scholar
  40. 40.
    Sureda A, Mataix R, Hernandez-Navarro F, et al.: Autologous stem cell transplantation for poor prognosis Hodgkin’s disease in first complete remission: a retrospective study from the Spanish GEL-TAMO Cooperative Group. Bone Marrow Transplant 1997, 20:283–288.PubMedCrossRefGoogle Scholar
  41. 41.
    Moreau P, Fleury J, Brice P, et al.: Early intensive therapy with autologous stem cell transplantation in advanced Hodgkin’s disease: retrospective analysis of 158 cases from the French registry. Bone Marrow Transplant 1998, 21:787–793. This retrospective analysis, like that of Nademanee et al. [11•], suggests a potential role for upfront transplantation for patients with poor-risk advanced HD.PubMedCrossRefGoogle Scholar
  42. 42.
    Moskowitz CH, Yahalom J, Straus D, et al.: The use of Stanford V overcomes the poor prognostic features among patients with advanced stage Hodgkin’s disease (HD) [abstract]. Blood 1998, 92:2579a. The data from this report suggest that Stanford V is superior to ABVD among patients with advanced HD, regardless of adverse prognostic features.Google Scholar
  43. 43.
    Lee SM, Radford JA, Ryder WDJ, et al.: Prognostic factors for disease progression in advanced Hodgkin’s disease: an analysis of patients aged under 60 years showing no progression in the first 6 months after starting primary chemotherapy. Br J Cancer 1997, 75:110–115.PubMedGoogle Scholar
  44. 44.
    Moskowitz CH, Nimer SD, Zelenetz AD, et al.: A 2-step comprehensive high-dose chemoradiotherapy second-line program for relapsed and refractory Hodgkin disease: analysis by intent to treat and development of a prognostic model. Blood 2001, 97:616–623.PubMedCrossRefGoogle Scholar
  45. 45.
    Nademanee A, O’Donnell MR, Snyder DS, et al.: High-dose chemotherapy with or without total body irradiation followed by autologous bone marrow and/or peripheral blood stem cell transplantation for patients with relapsed and refractory Hodgkin’s disease: results in 85 patients with analysis of prognostic factors. Blood 1995, 85:1381–1390.PubMedGoogle Scholar
  46. 46.
    Linch DC, Winfeld D, Goldstone AH, et al.: Dose intensification with autologous bone-marrow transplantation in relapsed and resistant Hodgkin’s disease: results of BNLI randomised trial. Lancet 1993, 341:1051–1054.PubMedCrossRefGoogle Scholar
  47. 47.
    Yuen AR, Rosenberg SA, Hoppe RT, et al.: Comparison between conventional salvage therapy and high-dose therapy with autografting for recurrent or refractory Hodgkin’s disease. Blood 1997, 89:814–822.PubMedGoogle Scholar
  48. 48.
    Schmitz N, Sextro M, Pfistner N, et al.: High-dose therapy (HDT) followed by hematopoietic stem cell transplantation (HSCT) for relapsed chemosensitive Hodgkin’s disease (HD): final results of a randomized GHSG and EBMT trial (HD-R1) [abstract]. Proc ASCO 1999, 18:2a.Google Scholar
  49. 49.
    André M, Henry-Amar M, Pico J, et al.: Comparison of high-dose therapy and autologous stem-cell transplantation with conventional therapy for Hodgkin’s disease induction failure: a case control study. J Clin Oncol 1999, 17:222–229.PubMedGoogle Scholar
  50. 50.
    Lazarus HM, Rowlings PA, Zhang M, et al.: Autotransplants for Hodgkin’s disease in patients never achieving remission: a report from the autologous blood and marrow transplant registry. J Clin Oncol 1999, 17:534–545.PubMedGoogle Scholar

Copyright information

© Current Science Inc 2001

Authors and Affiliations

  • Tarun Kewalramani
    • 1
  • Craig H. Moskowitz
    • 1
  1. 1.Memorial Sloan-Kettering Cancer CenterNew YorkUSA

Personalised recommendations